Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition.

CONTEXT The Bcl-2 family of proteins regulates apoptosis in various models and may represent a promising therapeutic target in human malignancies. OBJECTIVE/METHODS We evaluated the sensitivity of thyroid carcinoma cell lines (two papillary, one follicular, two anaplastic, three medullary) in vitro to BH3I-1 and BH3I-2', two cell-permeable inhibitors of the Bcl-2 homology (BH)-3 domain-mediated interaction between proapoptotic and antiapoptotic Bcl-2 family members. The thyroid carcinoma cell line FRO was stably transfected with cDNA for Bcl-2 or constitutively active Akt and evaluated for sensitivity to BH3-domain inhibition. RESULTS BH3-domain inhibition disrupted the mitochondrial membrane potential in thyroid carcinoma cells, induced caspase-dependent apoptosis, and potently sensitized them to sublethal concentrations of doxorubicin and the proteasome inhibitor bortezomib (Velcade). Overexpression of constitutively active Akt suppressed BH3I-1-induced cell death. Bcl-2-overexpressing FRO cells were more resistant to conventional chemotherapeutic agents (such as doxorubicin) but significantly more sensitive to BH3I-1 than control cells and were found to overexpress caspase-9, caspase-8, Bmf, Bok, and Bik transcripts and express less A1, BRaf, and FLIP transcripts. CONCLUSIONS Bcl-2 expression protects thyroid carcinomas against chemotherapy-induced apoptosis. Nevertheless, overexpression of Bcl-2 may result in "oncogene addiction" of the cancer cell, which can be exploited by using BH3-domain inhibitors alone or in combination with other agents, including conventional chemotherapeutics (such as doxorubicin) or novel targeted therapies (such as the proteasome inhibitor bortezomib), for the treatment of aggressive thyroid cancer, including the medullary and anaplastic types.

[1]  Tobias Schmelzle,et al.  Functional role and oncogene-regulated expression of the BH3-only factor Bmf in mammary epithelial anoikis and morphogenesis , 2007, Proceedings of the National Academy of Sciences.

[2]  D. McMillin,et al.  Targeting BRAFV600E in thyroid carcinoma: therapeutic implications , 2007, Molecular Cancer Therapeutics.

[3]  K. Garber.  New insights into oncogene addiction found. , 2007, Journal of the National Cancer Institute.

[4]  Michael T. Certo,et al.  Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. , 2007, The Journal of clinical investigation.

[5]  D. McMillin,et al.  Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. , 2006, The Journal of clinical endocrinology and metabolism.

[6]  P. Richardson,et al.  Proteasome inhibition as a new therapeutic principle in hematological malignancies. , 2006, Current drug targets.

[7]  L. Galluzzi,et al.  Mitochondria as therapeutic targets for cancer chemotherapy , 2006, Oncogene.

[8]  D. McMillin,et al.  Fas Signaling in Thyroid Carcinomas Is Diverted from Apoptosis to Proliferation , 2006, Clinical Cancer Research.

[9]  C. Stein,et al.  A pharmacologic target of G3139 in melanoma cells may be the mitochondrial VDAC. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[10]  S. Armstrong,et al.  Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. , 2006, Cancer cell.

[11]  A. Khvorova,et al.  Gene profiling study of G3139- and Bcl-2-targeting siRNAs identifies a unique G3139 molecular signature , 2006, Cancer Gene Therapy.

[12]  P. Richardson,et al.  Proteasome inhibitors as therapeutics. , 2005, Essays in biochemistry.

[13]  P. Marks,et al.  Novel Histone Deacetylase Inhibitors in the Treatment of Thyroid Cancer , 2005, Clinical Cancer Research.

[14]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[15]  R. Herbst,et al.  Oblimersen Sodium (Genasense bcl-2 Antisense Oligonucleotide) , 2004, Clinical Cancer Research.

[16]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[17]  S. Korsmeyer,et al.  Cell Death Critical Control Points , 2004, Cell.

[18]  Suzanne Cory,et al.  The Bcl-2 family: roles in cell survival and oncogenesis , 2003, Oncogene.

[19]  N. Mitsiades,et al.  Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells. , 2002, The American journal of pathology.

[20]  I. Weinstein.  Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.

[21]  S. Shangary,et al.  Peptides derived from BH3 domains of Bcl-2 family members: a comparative analysis of inhibition of Bcl-2, Bcl-x(L) and Bax oligomerization, induction of cytochrome c release, and activation of cell death. , 2002, Biochemistry.

[22]  I. Enyedy,et al.  Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. , 2001, Journal of medicinal chemistry.

[23]  W. Zong,et al.  BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. , 2001, Genes & development.

[24]  S. Korsmeyer,et al.  Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and Death , 2001, Science.

[25]  K. Vousden,et al.  PUMA, a novel proapoptotic gene, is induced by p53. , 2001, Molecular cell.

[26]  Kam Y. J. Zhang,et al.  Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3 , 2001, Nature Cell Biology.

[27]  T. Mitchison,et al.  Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL , 2001, Nature Cell Biology.

[28]  J. Lammers,et al.  Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1 , 2000, Current Biology.

[29]  I. Stamenkovic,et al.  Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand. , 2000, Cancer research.

[30]  S. Srinivasula,et al.  Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[31]  T. Taniguchi,et al.  Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. , 2000, Science.

[32]  E. Alnemri,et al.  Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. , 2000, Cancer research.

[33]  R. Lutz,et al.  Bak BH3 Peptides Antagonize Bcl-xL Function and Induce Apoptosis through Cytochrome c-independent Activation of Caspases* , 1999, The Journal of Biological Chemistry.

[34]  J C Reed,et al.  Ca2+-induced apoptosis through calcineurin dephosphorylation of BAD. , 1999, Science.

[35]  N. Mitsiades,et al.  Fas/Fas ligand up-regulation and Bcl-2 down-regulation may be significant in the pathogenesis of Hashimoto's thyroiditis. , 1998, The Journal of clinical endocrinology and metabolism.

[36]  J. Fagin,et al.  Identification of rapid turnover transcripts overexpressed in thyroid tumors and thyroid cancer cell lines: use of a targeted differential RNA display method to select for mRNA subsets. , 1997, Nucleic acids research.

[37]  P. Nowell,et al.  Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. , 1984, Science.

[38]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.